Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Collegium Pharma (NQ: COLL )

37.79 +0.23 (+0.61%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 347,752
Open 37.54
Bid (Size) 35.11 (1)
Ask (Size) 37.98 (1)
Prev. Close 37.56
Today's Range 37.25 - 37.89
52wk Range 20.95 - 40.95
Shares Outstanding 32,213,751
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Organon Stock Sees Relative Strength Rating Rise To 91
On Tuesday, Organon[ stock hit an key technical milestone, seeing its Relative Strength Rating jump to 91, up from 88 the day before. 
Via Investor's Business Daily
Organon Stock Earns Relative Strength Rating Upgrade; Hits Key Threshold
On Tuesday, generic drug maker Organon stock had its Relative Strength (RS) Rating upgraded to 83, up from 78 a day earlier. 
Via Investor's Business Daily

Performance

YTD
+21.01%
+21.01%
1 Month
+8.31%
+8.31%
3 Month
+9.95%
+9.95%
6 Month
+2.72%
+2.72%
1 Year
+60.88%
+60.88%

More News

Read More
The Analyst Verdict: Collegium Pharmaceutical In The Eyes Of 4 Experts
Via Benzinga
COLL Stock Earnings: Collegium Pharmaceutical Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Collegium Reports Second Quarter 2024 Financial Results
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Demystifying Collegium Pharmaceutical: Insights From 4 Analyst Reviews
Via Benzinga
Critical Insights From Collegium Pharmaceutical Analyst Ratings: What You Need To Know
Via Benzinga
Where Collegium Pharmaceutical Stands With Analysts
Via Benzinga
In a market where value is scarce, NASDAQ:COLL offers a refreshing opportunity with its solid fundamentals.
Via Chartmill
Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium to Report Second Quarter 2024 Financial Results on August 8, 2024
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
NASDAQ:COLL is an undervalued gem with solid fundamentals.
Via Chartmill
Dr. Reddy's Labs Stock Sees Improved Technical Strength
Via Investor's Business Daily
7 Biotech Stocks to Buy on the Dip: June 2024
Via InvestorPlace
NASDAQ:COLL appears to be flying under the radar despite its strong fundamentals.
Via Chartmill
Collegium Obtains Six Month Extension of U.S. Pediatric Exclusivity for Nucynta Franchise
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium to Participate in Jefferies Global Healthcare Conference
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Announces $35 Million Accelerated Share Repurchase Program
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
COLL Stock Earnings: Collegium Pharmaceutical Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Collegium Reports First Quarter 2024 Financial Results
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Announces CEO Transition
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium to Report First Quarter 2024 Financial Results on May 9, 2024
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium to Participate in 23rd Annual Needham Virtual Healthcare Conference
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.